What is Biogen's BYOOVIZ — total revenue?

Biogen (BIIB) reported BYOOVIZ — total revenue of $0 in Q1 2026.

How has Biogen's BYOOVIZ — total revenue changed year-over-year?

Biogen's BYOOVIZ — total revenue decreased by 100.0% year-over-year, from $8.9M to $0.

What does BYOOVIZ — total revenue mean?

This metric represents the total gross sales generated from the commercialization of the specific biosimilar product within the company's portfolio. It reflects the market adoption and competitive positioning of the asset against reference biologics in the ophthalmology therapeutic area. Tracking this revenue stream provides insight into the company's success in diversifying its revenue base beyond traditional neurology franchises.

Biogen BIIB BYOOVIZ — Total Revenue

Other product segments

TYSABRI

$441.5M+15.7%

SPINRAZA

$374M-11.8%

VUMERITY

$179M+29.0%

AVONEX

$163.2M-2.2%

SKYCLARYS

$150.7M+21.6%

BENEPALI

$122.1M+9.7%

TECFIDERA

$109.5M-46.9%

PLEGRIDY

$64.3M+8.1%

ZURZUVAE

$55.4M+100%

IMRALDI

$49.6M+4.6%

QALSODY

$32.5M+110%

FLIXABI

$10.5M-19.8%

FAMPYRA

$0-100%

FUMADERM And ADUHELM

$0-100%

TOFIDENCE

$0-100%

Similar metrics at other companies

BMYYervoy — Total Revenues

$651M+4.3%

BMRNVOXZOGO — Total revenues

$219.88M+2.9%

OGNOther Biosimilars — Revenue

$24M+380%

SUPNGOCOVRI — Total revenues

$35.24M+14.8%

BMYOpdivo — Total Revenues

$2.15B-5.3%

AMRXBiosimilar — Net revenue

$22.3M-21.9%

Other financials

Income statement

See full

Revenue$2.5B+1.9%

Gross profit$1.8B+0.8%

Operating income$610.7M—

Net income$319.5M+32.8%

EPS (diluted)$2.15+31.1%

Balance sheet

See full

Cash & equivalents$3.4B+30.2%

Total debt$6.6B+34.7%

Total equity$18.7B+9.9%

Total assets$29.5B+5.2%

Cash flow

See full

Operating cash flow$645.5M+149%

CapEx$51.2M+38.0%

Free cash flow$594.3M+167%

Valuation

See full

Market cap$31.89B+72.3%

Enterprise value$35.07B+57.0%

P/E22.5×+10.4×

P/S3.2×+1.4×

Profitability

See full

Gross margin75.5%-0.1pp

Operating margin22.9%—

Net margin14.3%-0.8pp

FCF margin24.4%-0.4pp

Returns & leverage

See full

Return on equity8%-1.2pp

Debt / equity0.4×+0.1×

Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's byooviz — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's BYOOVIZ — total revenue?: Biogen (BIIB) reported BYOOVIZ — total revenue of $0 in Q1 2026.
How has Biogen's BYOOVIZ — total revenue changed year-over-year?: Biogen's BYOOVIZ — total revenue decreased by 100.0% year-over-year, from $8.9M to $0.
What does BYOOVIZ — total revenue mean?: This metric represents the total gross sales generated from the commercialization of the specific biosimilar product within the company's portfolio. It reflects the market adoption and competitive positioning of the asset against reference biologics in the ophthalmology therapeutic area. Tracking this revenue stream provides insight into the company's success in diversifying its revenue base beyond traditional neurology franchises.